A venture capital firm made about $470 million on a buzzy biotech’s $8 billion acquisition, and has its eye on these promising areas next

Eli Lilly & Co.’s about $8 billion acquisition of biotech Loxo Oncology could mean a $470 million payday for venture-capital firm Aisling Capital. Aisling Capital was a founding investor in Loxo and most recently held a 6.6% stake.  Aisling Capital managing partner Steve Elms told Business Insider about the other biotechs and scientific areas the firm is intrigued by. 

Pharma giant Eli Lilly & Co.’s Monday acquisition of biotech Loxo Oncology for $8 billion

Continue reading...